AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02414347 — intervention group
Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT02869945 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Identification of COMT HH, COMT HL or COMT LL genes
Description: COMT HH, COMT HL or COMT LL genes identification
Study NCT02869945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI with resting state scan
Description: MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
Study NCT02869945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain MPET
Description: Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
Study NCT02560389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill packaged to resemble levodopa
Study NCT02560389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
Study NCT02049112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salivary equivalent
Description: 14-day treatment with salivary equivalent sticks
Study NCT02049112 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aequasyal
Description: 14-day treatment with Aequasyal oral spray
Study NCT02049112 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biotene
Description: 14-day treatment with Biotene oral spray
Study NCT02716298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study NCT02716298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: contact lens
Study NCT02314104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
Study NCT00941642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
Study NCT00941642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
Study NCT00269477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT00269477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT03442699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
Study NCT03145051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: a nasal irrigation care
Study NCT03145051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respimer Netiflow
Description: a nasal irrigation care
Study NCT00523523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy + auditory rhythm cues
Description: The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
Study NCT00523523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Description: The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
Study NCT03209518 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuplin PRO for Injection Kit 22.5 mg
Study NCT03163459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective brain cooling by cold saline perfusion
Description: During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
Study NCT03163459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical thrombectomy
Description: conventional mechanical thrombectomy using Solitaire
Study NCT01192776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
Study NCT01192776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-body Cooling
Description: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
Study NCT03163459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: conventional mechanical thrombectomy using Solitaire
Study NCT03257969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The DROP program of pharmaceutical interventions
Description: Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
Study NCT03257969 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
Study NCT00966355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
Study NCT00966355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
Study NCT00966355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
Study NCT01028495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-0201 plus Gemcitabine
Description: RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
Study NCT03706001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 0.625 mcg/puff
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 mcg/puff
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 mcg/puff
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 mcg/puff
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium-18 lactose powder
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactose powder
Study NCT02175342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 mcg/puff
Study NCT02175342 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Study NCT02175342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Study NCT02175342 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Handihaler
Study NCT02175342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handihaler
Study NCT00006110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
Study NCT00006110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous infusion every 3 weeks for four cycles
Study NCT00006110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
Study NCT00006110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
Study NCT00006110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
Study NCT00792116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum Chewing
Study NCT01658397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Ten day fast
Study NCT04219839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC + Educational Videos Designed Especially for post-transplant patients
Description: Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
Study NCT00435188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity counseling program
Description: A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 100 g high fibre flour
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 2
Description: 98 g high fibre flour + 2 g guar gum
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 3
Description: 88 g high fibre flour + 2 g guar gum + 10 g legume flour
Study NCT00960167 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT or IMRT
Description: All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)
Study NCT03464474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital holographic microscopy
Description: Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
Study NCT00509353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00509353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00509353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iobenguane I 131
Study NCT03850405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
Study NCT03365453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frailty evaluation
Description: frailty and comorbidity scores
Study NCT03722407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 5 mg tablets, 4 per dose
Study NCT03337906 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT01476306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
Study NCT01476306 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in this group will receive care as they usually do with the physician.
Study NCT03951753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT03951753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC
Study NCT03951753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02623608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference breakfast
Description: A high fat, high calorie breakfast
Study NCT02623608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 1
Description: A high fat, high calorie breakfast including the Active Ingredient 1
Study NCT02623608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 2
Description: A high fat, high calorie breakfast including the Active Ingredient 2
Study NCT02623608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 3
Description: A high fat, high calorie breakfast including the Active Ingredient 3
Study NCT02623608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 4
Description: A high fat, high calorie breakfast including the Active Ingredient 4
Study NCT00098540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00098540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01990716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colonic Biopsy
Description: Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time.
Study NCT01587417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 187004 CL
Description: 1 single dose per subject as oral solution
Study NCT01587417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004 CL
Description: 1 single dose per subject as oral solution
Study NCT00989859 — intervention group
Intervention type: DEVICE
Intervention: Plethysmographic monitoring
Description: Plethysmographic monitoring
Study NCT01790516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
Study NCT01790516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
Study NCT01790516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: daily radiation for 7 weeks
Study NCT03001479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid
Description: HMF with additional hydrolyzed protein
Study NCT04106271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dyadic pain management program
Description: a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
Study NCT04929860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social marketing campaign
Description: social marketing campaign delivered over 4 weeks in 4 separate sessions
Study NCT00135902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement
Description: Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
Study NCT00135902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 17 alpha-hydroxy progesterone caproate and Placebo supplement
Description: Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 4
Description: 83 g high fibre flour + 2 g guar gum + 15 g legume flour
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 5
Description: 96 g high fibre flour + 4 g guar gum
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 6
Description: 86 g high fibre flour + 4 g guar gum + 10 g legume flour
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 7
Description: 81 g high fibre flour + 4 g guar gum + 15 g legume flour
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 8
Description: 94 g high fibre flour + 6 g guar gum
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 9
Description: 98 g high fibre flour + 2 g konjac mannan
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 10
Description: 96 g high fibre flour + 4 g konjac mannan
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 11
Description: 100 g low fibre flour
Study NCT02671214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 1
Description: 85 g high fibre flour + 15 g legume flour
Study NCT03700372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOWA Approach Cardiac Ablation System
Description: Epicardial ablation using the IOWA Approach Cardiac Ablation System
Study NCT03409731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ABSORB GT1 BVS
Description: Patients receiving Absorb GT1 BVS
Study NCT02582385 — intervention group
Intervention type: OTHER
Intervention: in-situ cytokine expression